The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Open accessAbstract
Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for DNA homologous recombination repair (HRR). This review provides an update on oral poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of BC. Olaparib and talazoparib are PARP inhibitors approved as monotherapies for deleterious/suspected deleterious germline BRCA-mutated, HER2-negative BC. Olaparib is approved in the USA for metastatic BC and in Europe for locally advanced/metastatic BC. Talazoparib is approved for locally advanced/metastatic BC in the USA and Europe. In phase 3 trials, olaparib and talazoparib monotherapies demonstrated significant progression-free survival benefits compared with chemotherapy. Common toxicities were effectively managed by supportive treatment and dose interruptions/reductions. Veliparib combined with platinum-based chemotherapy has also shown promise for locally advanced/metastatic BC in a phase 3 trial. Differences in efficacy and safety across PARP inhibitors (olaparib, talazoparib, veliparib, niraparib, rucaparib) may relate to differences in potency of PARP trapping on DNA and cytotoxic specificity. PARP inhibitors are being investigated in early BC, in novel combinations, and in patients without germline BRCA mutations, including those with somatic BRCA mutations and other HRR gene mutations. Ongoing phase 2/3 studies include PARP inhibitors combined with immune checkpoint inhibitors for the treatment of triple-negative BC. Wider access to testing for BRCA and other mutations, and to genetic counseling, are required to identify patients who could benefit from PARP inhibitor therapy. The advent of PARP inhibitors has potential benefits for BC treatment beyond the locally advanced/metastatic setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954 · cited 1×
“In carriers of BRCA1 or BRCA2 mutations, the risk of developing BC by 80 years of age is as high as 70%, compared with a 10% risk for women in the general population [9, 11].”
BackgroundPARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Self-citation3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationTargeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Roy, R., Chun, J., & Powell, S. N. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3181 · Cited by 1,469
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationAutosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction
Claus, E. B., Risch, N., & Thompson, W. D. (1994) · Cancer · doi:10.1002/1097-0142(19940201)73:3<643::aid-cncr2820730323>3.0.co;2-5 · Cited by 942
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Self-citationA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743 · cited 6×
“Evaluation of mutations in various HRR genes could be fundamental to identify patients suitable for PARP inhibitor therapy, as has been suggested by studies of prostate cancer [56].”
BackgroundInfluentialAbraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response
Wang, B., Matsuoka, S., Ballif, B. A., Zhang, D., Smogorzewska, A., Gygi, S. P., & Elledge, S. J. (2007) · Science · doi:10.1126/science.1139476 · Cited by 695
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 672
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., Robson, M., Sherman, M., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0775 · Cited by 669
Thompson, M. E., Jensen, R. A., Obermiller, P. S., Page, D. L., & Holt, J. T. (1995) · Nature Genetics · doi:10.1038/ng0495-444 · Cited by 585
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Ubiquitin-Binding Protein RAP80 Mediates BRCA1-Dependent DNA Damage Response
Kim, H., Chen, J., & Yu, X. (2007) · Science · doi:10.1126/science.1139621 · Cited by 540
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz189 · Cited by 512
Tung, N. M., Robson, M. E., Ventz, S., Santa-Maria, C. A., Nanda, R., Marcom, P. K., Shah, P. D., Ballinger, T. J., Yang, E. S., Vinayak, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02151 · Cited by 508
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
Anderson, W. F., Jatoi, I., Tse, J., & Rosenberg, P. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8162 · Cited by 495
BRCA1 is a component of the RNA polymerase II holoenzyme
Scully, R., Anderson, S. F., Chao, D. M., Wei, W., Ye, L., Young, R. A., Livingston, D. M., & Parvin, J. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5605 · Cited by 454
Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Wahner-Hendrickson, A. E., Forero, A., Anders, C., Wulf, G. M., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1029 · Cited by 454
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2098 · Cited by 412
Self-citationSardanelli, F., Podo, F., Santoro, F., Manoukian, S., Bergonzi, S., Trecate, G., Vergnaghi, D., Federico, M., Cortesi, L., Corcione, S., et al. (2011) · Investigative Radiology · doi:10.1097/rli.0b013e3181f3fcdf · Cited by 337
Self-citationTung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A., Gelpi, J. B., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 332
for the PROMISE study team, Hann, K. E. J., Freeman, M., Fraser, L., Waller, J., Sanderson, S. C., Rahman, B., Side, L., Gessler, S., & Lanceley, A. (2017) · BMC Public Health · doi:10.1186/s12889-017-4375-8 · Cited by 314
Diéras, V., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30447-2 · Cited by 311
進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar, L. B., Barrios, C. H., van den Bergh, J. P., et al. (2018) · Annals of Oncology · Cited by 296
Self-citationCragun, D., Weidner, A., Lewis, C., Bonner, D., Kim, J., Vadaparampil, S. T., & Pal, T. (2017) · Cancer · doi:10.1002/cncr.30621 · Cited by 293
Krohe, M., Eek, D., Mazar, I., Horsfield, A., Pompilus, F., Friebe, R., & Shields, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106629 · Cited by 265
A systematic review of the international prevalence of BRCA mutation in breast cancer
Armstrong, N., Ryder, S., Forbes, C., Ross, J., & Quek, R. G. (2019) · Clinical Epidemiology · doi:10.2147/clep.s206949 · Cited by 259
BRCA1 and BRCA2 mutations and treatment strategies for breast cancer
Godet, I., & M. Gilkes, D. (2017) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000228 · Cited by 250
Walsh, C. S. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.02.017 · Cited by 245
The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair
Starita, L. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00042-5 · Cited by 235
BRCA1/2 testing: therapeutic implications for breast cancer management
Tung, N. M., & Garber, J. E. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0127-5 · Cited by 221
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Eikesdal, H. P., Yndestad, S., Elzawahry, A., Llop-Guevara, A., Gilje, B., Blix, E. S., Espelid, H., Lundgren, S., Geisler, J., Vagstad, G., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.009 · Cited by 219
Litton, J. K., Scoggins, M. E., Hess, K. R., Adrada, B. E., Murthy, R. K., Damodaran, S., DeSnyder, S. M., Brewster, A. M., Barcenas, C. H., Valero, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01304 · Cited by 195
Maajani, K., Jalali, A., Alipour, S., Khodadost, M., Tohidinik, H. R., & Yazdani, K. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.01.006 · Cited by 191
McCarthy, A. M., Bristol, M., Domchek, S. M., Groeneveld, P. W., Kim, Y., Motanya, U. N., Shea, J. A., & Armstrong, K. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.0019 · Cited by 182
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Ancevski Hunter, K., Socinski, M. A., & Villaruz, L. C. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0308-6 · Cited by 173
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C. A., Huober, J., Stefek, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.471 · Cited by 160
Self-citationBRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer
Rosenberg, S. M., Ruddy, K. J., Tamimi, R. M., Gelber, S. I., Schapira, L., Come, S. E., Borges, V. F., Larsen, B. G., Garber, J. E., & Partridge, A. H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5941 · Cited by 159
Winter, C., Nilsson, M., Olsson, E., George, A. M., Chen, Y., Kvist, A., Törngren, T., Vallon‐Christersson, J., Hegardt, C., Häkkinen, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw209 · Cited by 158
Lafourcade, A., His, M., Baglietto, L., Boutron‐Ruault, M., Dossus, L., & Rondeau, V. (2018) · BMC Cancer · doi:10.1186/s12885-018-4076-4 · Cited by 154
Ettl, J., Quek, R. G. W., Lee, K. H., Rugo, H. S., Hurvitz, S. A., Gonçalvès, A., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martín, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy257 · Cited by 153
Self-citationPARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
Min, A., & Im, S. (2020) · Cancers · doi:10.3390/cancers12020394 · Cited by 148
Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Balmañà, J., Fasching, P. A., Hurvitz, S. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1891 · Cited by 141
Self-citationForbes, C. A., Fayter, D., de Kock, S., & Quek, R. G. W. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189627 · Cited by 141
Validity of Models for Predicting BRCA1 and BRCA2 Mutations
Parmigiani, G., Chen, S., Iversen, E. S., Friebel, T. M., Finkelstein, D. M., Anton-Culver, H., Ziogas, A., Weber, B. L., Eisen, A. F., Malone, K. E., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-7-200710020-00002 · Cited by 140
Unique Features of Young Age Breast Cancer and Its Management
Lee, H., & Han, W. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.4.301 · Cited by 137
Robson, M. E., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Tung, N., Armstrong, A. C., Dymond, M., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.031 · Cited by 136
Decision making for breast cancer prevention among women at elevated risk
Padamsee, T. J., Wills, C. E., Yee, L. D., & Paskett, E. D. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0826-5 · Cited by 113
Grindedal, E. M., Heramb, C., Karsrud, I., Ariansen, S. L., Mæhle, L., Undlien, D. E., Norum, J., & Schlichting, E. (2017) · BMC Cancer · doi:10.1186/s12885-017-3422-2 · Cited by 107
Somlo, G., Frankel, P. H., Arun, B., Ma, C. X., García, A. A., Cigler, T., Cream, L., Harvey, H. A., Sparano, J. A., Nanda, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2714 · Cited by 99
Robson, M. E., Ruddy, K. J., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Li, W., Tung, N., Armstrong, A. C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.023 · Cited by 93
Hurvitz, S. A., Gonçalvès, A., Rugo, H. S., Lee, K.-H., Fehrenbacher, L., Mina, L. A., Diab, S., Blum, J. L., Chakrabarti, J., Elmeliegy, M. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0493 · Cited by 88
Self-citationOlaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation
Caulfield, S. E., Christine C. Davis, P., & Byers, K. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.2.6 · Cited by 87
Breast Cancer Risks and Risk Prediction Models
Engel, C., & Fischer, C. (2015) · Breast Care · doi:10.1159/000376600 · Cited by 78
Sourvinos, G., & Spandidos, D. A. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8379 · Cited by 78
Jones, T., McCarthy, A. M., Kim, Y., & Armstrong, K. (2017) · Cancer Medicine · doi:10.1002/cam4.1120 · Cited by 69
Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast Cancer
Park, I. H., Lee, K. S., & Ro, J. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.09.001 · Cited by 68
Inherited and acquired alterations in development of breast cancer
Ottini, L., Rizzolo, P., Silvestri, V., & Falchetti, M. (2011) · The Application of Clinical Genetics · doi:10.2147/tacg.s13226 · Cited by 66
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
Aleskandarany, M. A., Caracappa, D., Nolan, C. C., Macmillan, R. D., Ellis, I. O., Rakha, E. A., & Green, A. R. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3306-6 · Cited by 60
Tung, N., Robson, M. E., Ventz, S., Santa-Maria, C. A., Marcom, P. K., Nanda, R., Shah, P. D., Ballinger, T. J., Yang, E. S.-H., Melisko, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1002 · Cited by 60
Factors Associated with Breast Cancer Mortality after Local Recurrence
Dent, R. A., Valentini, A., Hanna, W. M., Rawlinson, E., Rakovitch, E., Sun, P., & Narod, S. A. (2014) · Current Oncology · doi:10.3747/co.21.1563 · Cited by 57
Litton, J. K., Scoggins, M. E., Ramirez, D. L., Murthy, R. K., Whitman, G. J., Hess, K. R., Adrada, B. E., Moulder, S. L., Barcenas, C. H., Valero, V., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0052-4 · Cited by 57
Pal, T., Cragun, D., Lewis, C., Doty, A., Rodriguez, M., Radford, C., Thompson, Z., Kim, J., & Vadaparampil, S. T. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0381 · Cited by 56
Disparities in genetic services utilization in a random sample of young breast cancer survivors
Nikolaidis, C., Duquette, D. A., Mendelsohn‐Victor, K., Anderson, B., Copeland, G. E., Milliron, K. J., Merajver, S. D., Janz, N. K., Northouse, L., Duffy, S. A., et al. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0349-1 · Cited by 56
Henderson, B. R. (2012) · Scientifica · doi:10.6064/2012/796808 · Cited by 55
Stuckey, A. R., Febbraro, T., Laprise, J. K., Wilbur, J. S., Lopes, V., & Robison, K. M. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000073 · Cited by 54
Preoperative genetic testing affects surgical decision making in breast cancer patients
Lokich, E., Stuckey, A. R., Raker, C., Wilbur, J. S., Laprise, J. K., & Gass, J. S. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.05.028 · Cited by 51
Population Based Testing for Primary Prevention: A Systematic Review
Manchanda, R., & Gaba, F. (2018) · Cancers · doi:10.3390/cancers10110424 · Cited by 51
Alemar, B., Gregório, C., Herzog, J., Bittar, C. M., Netto, C. B. O., Artigalás, O., Schwartz, I. V. D., Coffa, J., Camey, S. A., Weitzel, J. N., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187630 · Cited by 49
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F. M., Poortmans, P. M., Rubio, I. T., Zackrisson, S., & Senkus, E. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2158 · Cited by 48
Hodgson, D., Lai, Z., Dearden, S. P., Barrett, J. C., Harrington, E. A., Timms, K. M., Lanchbury, J. S. S., Wu, W., Allen, A., Senkus, E., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2154 · Cited by 45
Cortesi, L., Razzaboni, E., Toss, A., Matteis, E. D., Marchi, I., Medici, V., Tazzioli, G., Andreotti, A., Santis, G. D., Pignatti, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt422 · Cited by 39
Self-citationFirst-Line Chemotherapy for Metastatic Breast Cancer
Telli, M. L., & Carlson, R. W. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.007 · Cited by 38
Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation
Hull, L. E., Haas, J. S., & Simon, S. R. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.10.015 · Cited by 37
Diéras, V. C., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.008 · Cited by 32
Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalvès, A., Lee, K.-H., Fehrenbacher, L., Mina, L. A., Diab, S., Woodward, N. E., Yerushalmi, R., et al. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz085 · Cited by 30
Self-citationToss, A., Molinaro, E., Venturelli, M., Domati, F., Marcheselli, L., Piana, S., Barbieri, E., Grandi, G., Piombino, C., Marchi, I., et al. (2020) · Cancers · doi:10.3390/cancers12051252 · Cited by 27
Self-citationManagement of Hereditary Breast Cancer
Eccles, D., Simmonds, P., Goddards, J., Coultas, M., Lalloo, F. I., Evans, D. G., & Haites, N. E. (1999) · Disease Markers · doi:10.1155/1999/809015 · Cited by 26
Werner, T. L., Sachdev, J. C., Swisher, E. M., Gutiérrez, M., Kittaneh, M., Stein, M. N., Xiong, H., Dunbar, M., Sullivan, D. M., Komarnitsky, P. B., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1488 · Cited by 19
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
Shao, N., Shi, Y., Yu, L., Ye, R., Shan, Z., Zhang, Z., Zhang, Y., & Lin, Y. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.30721 · Cited by 18
Frey, M. K., Kopparam, R. V., Zhou, Z. N., Fields, J. C., Buskwofie, A., Carlson, A. D., Caputo, T. A., Holcomb, K., & Chapman‐Davis, E. (2018) · Cancer · doi:10.1002/cncr.31856 · Cited by 17
Tung, N., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Li, W., Armstrong, A. C., Conte, P., Wu, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1052 · Cited by 14
Gay, C. M., & Byers, L. A. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.004 · Cited by 14
Hyman, D. M., Zelnak, A. B., Bauer, T. M., Ulahannan, S. V., Ford, J. M., Cesari, R., Hoyle, M., Chappey, C., Stewart, R. A., Conte, U., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps2660 · Cited by 12
Tutt, A. N. J., Stephens, C., Frewer, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps1112 · Cited by 12
Robson, M. E., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A. C., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-pd4-03 · Cited by 10
Pinilla, K., McMurtry, E., Vallier, A.-L., Grybowicz, L., Copson, E., Armstrong, A. C., Roylance, R. R., Qian, W., Demiris, N., Thomas, S., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-p3-10-05 · Cited by 10
Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-ct071 · Cited by 10
Self-citationAguirre, E., Amillano, K., Cortés, A., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct165 · Cited by 9
Mitri, Z. I., Vuky, J., Kemmer, K. A., Savin, M. A., Parmar, S. S., Kolodzie, A., Johnson, B., Williams-Belizaire, R., Gray, J. W., & Mills, G. B. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps1111 · Cited by 8
Bobbili, P. J., Olufade, T. O., DerSarkissian, M., Shenolikar, R. A., Yu, H., Duh, M. S., & Tung, N. (2020) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-020-00144-z · Cited by 8
Abraham, J., Vallier, A.-L., Qian, W., Machin, A., Grybowicz, L., Thomas, S., Harvey, C., McAdam, K., Hughes‐Davies, L., Roylance, R. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.tps605 · Cited by 8
Abstract 1724: Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
Wang, S., Sun, K., Xiao, Y., Feng, B., Mikule, K. W., Ramaswamy, S., Hanke, J. H., & Wang, J. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-1724 · Cited by 7
Arun, B., Han, H. S., Kaufman, B., Wildiers, H. P. M. W., Friedlander, M. L., Ayoub, J.-P., Puhalla, S. L., Bach, B. A., Dudley, M. W., Ratajczak, C. K., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-pd4-01 · Cited by 6
Abraham, J., Vallier, A.-L., Qian, W., Grybowicz, L., Thomas, S., Machin, A., Harvey, C., Chiu, E., McAdam, K., Hughes‐Davies, L., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-ot3-04-03 · Cited by 3
Cited by
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Demuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., et al. (2024) · Cancers · doi:10.3390/cancers16203441 · Cited by 14
“The PARPi olaparib, rucaparib, and niraparib were shown to induce synthetic lethality in tumors deficient in BRCA1/2 [17].”
BackgroundAromatase inhibitors and contralateral breast cancer in BRCA mutation carriers
Nemati Shafaee, M., Goutsouliak, K., Lin, H., Bevers, T. B., Gutierrez-Barrera, A., Bondy, M., & Arun, B. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06688-z · Cited by 12
Metadata
- Authors
- Cortesi, L., Rugo, H. S., & Jackisch, C.
- Venue
- Targeted Oncology
- Published
- 2021-03-12
- Volume
- 16
- Issue
- 3
- Pages
- 255-282
- ISSN
- 1776-2596 (ISSN-L)
- 1776-260X
- OpenAlex
- W3134914296
- Cited by
- 393
- References
- 110
- FWCI
- 22.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.